SB 756050
Alternative Names: 756050Latest Information Update: 05 Nov 2023
At a glance
- Originator GlaxoSmithKline
- Class Antihyperglycaemics
- Mechanism of Action GPBAR1 protein agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 28 Feb 2009 Phase-II clinical trials in Type-2 diabetes mellitus in USA (PO)